Edition:
United States

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

129.10EUR
7:56am EDT
Change (% chg)

€3.40 (+2.70%)
Prev Close
€125.70
Open
€127.50
Day's High
€129.50
Day's Low
€127.50
Volume
55,256
Avg. Vol
119,236
52-wk High
€129.85
52-wk Low
€97.24

Chart for

About

Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company is focused on various therapeutic areas, including oncology, neurosciences, rare diseases and consumer healthcare. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes... (more)

Overall

Beta: 0.67
Market Cap(Mil.): €10,699.00
Shares Outstanding(Mil.): 83.78
Dividend: 1.00
Yield (%): 0.80

Financials

  IPN.PA Industry Sector
P/E (TTM): 38.61 29.67 32.21
EPS (TTM): 3.26 -- --
ROI: 13.54 13.44 13.05
ROE: 18.72 15.16 14.90

BRIEF-Ipsen Q1 Sales up at 510.3 Million Euros

* IPSEN REPORTS STRONG Q1 2018 SALES GROWTH OF 23.1% AT CONSTANT EXCHANGE RATES

1:46am EDT

BRIEF-Ipsen Announces EMA Validation Of Filing Of New Application For Additional Indication For Cabometyx®

* ANNOUNCES EMA VALIDATION OF FILING OF A NEW APPLICATION FOR ADDITIONAL INDICATION FOR CABOMETYX®, FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

Mar 28 2018

BRIEF-Ipsen Receives Positive CHMP Opinion For Cabometyx

* IPSEN RECEIVES POSITIVE CHMP OPINION FOR CABOMETYX® (CABOZANTINIB) FOR THE FIRST-LINE TREATMENT OF ADULTS WITH INTERMEDIATE- OR POOR- RISK ADVANCED RENAL CELL CARCINOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Mar 23 2018

BRIEF-Ipsen Announces Health Canada Approval Of Dysport Therapeutic For Treatment Of Lower Limb Spasticity In Adults

* IPSEN ANNOUNCES HEALTH CANADA APPROVAL OF DYSPORT THERAPEUTIC (ABOBOTULINUMTOXINA) FOR THE TREATMENT OF LOWER LIMB SPASTICITY IN ADULTS

Mar 15 2018

French pharma group Ipsen sees more asset purchases, U.S. growth

PARIS French pharma company Ipsen expects to bring more drugs to combat cancer, rare diseases and mobility impairment into its pipeline this year and has around one billion euros ($1.25 billion) for asset purchases, its chief executive said.

Feb 15 2018

BRIEF-Ipsen FY IFRS Operating Income Up At 397.2 Million Euros

* IPSEN DELIVERS STRONG 2017 RESULTS WITH 21.1%1 SALES GROWTH AND CORE OPERATING MARGIN INCREASE OF 3.4 POINTS AND EXPECTS SIGNIFICANT FURTHER GROWTH IN SALES AND MARGIN IN 2018

Feb 15 2018

BRIEF-Ipsen Appoints Sotirios G. Stergiopoulos As Chief Medical Officer‍​

* DR SOTIRIOS G. STERGIOPOULOS APPOINTED AS IPSEN CHIEF MEDICAL OFFICER‍​ Further company coverage: (Gdynia Newsroom)

Jan 26 2018

BRIEF-Ipsen And Exelixis Announce Phase 3 Trial Results Of Cabozantinib Showing Benefit In Hepatocellular Carcinoma Patients

* EXELIXIS AND IPSEN ANNOUNCE PHASE 3 TRIAL RESULTS OF CABOZANTINIB DEMONSTRATING SIGNIFICANT OVERALL SURVIVAL BENEFIT IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA

Jan 16 2018

BRIEF-Ipsen Appoints Richard Paulson Executive VP And CEO Of Ipsen North America

* IPSEN APPOINTS RICHARD PAULSON EXECUTIVE VICE-PRESIDENT AND CHIEF EXECUTIVE OFFICER OF IPSEN NORTH AMERICA Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Jan 12 2018

BRIEF-Ipsen ‍Announces Results From Phase III Study of Dysport On Neurology​

* ‍ANNOUNCED RESULTS FROM PHASE III STUDY DEMONSTRATING EFFICACY AND SAFETY OF DYSPORT(ABOBOTULINUMTOXINA) IN ADULT PATIENTS ​

Nov 29 2017

Earnings vs. Estimates